Mesoblast (MESO) Net Margin (2014 - 2023)
Mesoblast (MESO) posted quarterly Net Margin of 1181.62% for Q2 2023, down 21691.0% year-on-year from N/an in Q2 2022, and down 23.18% on a QoQ basis from 959.26% in Q1 2023.
Mesoblast (MESO) Net Margin (2014 - 2023) Analysis & Trends
Mesoblast (MESO) has reported Net Margin for 10 consecutive years, with 1181.62% the latest figure, recorded in Q2 2023.
- Quarterly Net Margin fell 21691.0% year-over-year to 1181.62% in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 1005.14% (down 10897.0% YoY) and the FY2025 annual result came in at 593.92%, up 89636.0% from the prior year.
- Net Margin declined to 1181.62% in Q2 2023 per MESO's latest filing, from 959.26% in the prior quarter.
- Over the last five years, Net Margin for MESO reached as high as 122.7% in Q2 2020 and fell as low as 2396.35% in Q1 2019.
- A 5-year average of 1035.84% and a median of 1009.19% in 2019 frame the typical range for Net Margin.
- The largest YoY upside for Net Margin was 166291 bps in 2020 against a maximum downside of 158782 bps in 2020.
- Year by year, Net Margin stood at 1248.55% in 2019, then grew by 8 bps to 1146.45% in 2020, then jumped by 36 bps to 733.74% in 2021, then sank by 56 bps to 1147.42% in 2022, then decreased by 3 bps to 1181.62% in 2023.
- According to Business Quant data, Net Margin over the past three periods registered 1181.62%, 959.26%, and 1147.42% for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -1,181.62% |
| Mar 31, 2023 | -959.26% |
| Dec 31, 2022 | -1,147.42% |
| Sep 30, 2022 | -760.88% |
| Jun 30, 2022 | -964.70% |
| Mar 31, 2022 | -1,059.27% |
| Dec 31, 2021 | -733.74% |
| Sep 30, 2021 | -934.97% |
| Jun 30, 2021 | -674.21% |
| Mar 31, 2021 | -1,354.19% |
| Dec 31, 2020 | -1,146.45% |
| Sep 30, 2020 | -1,880.77% |
| Jun 30, 2020 | -122.70% |
| Mar 31, 2020 | -733.45% |
| Dec 31, 2019 | -1,248.55% |
| Sep 30, 2019 | -292.95% |
| Jun 30, 2019 | -1,053.69% |
| Mar 31, 2019 | -2,396.35% |
| Dec 31, 2018 | -2,021.69% |
| Sep 30, 2018 | -1,780.64% |